We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.00 | -0.12% | 12,156.00 | 12,126.00 | 12,128.00 | 12,258.00 | 12,114.00 | 12,114.00 | 1,961,686 | 16:35:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.57 | 188.01B |
From May 2019 to May 2024
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Wednesday that it has agreed to sell and license commercial rights to its Seroquel and Seroquel XR drugs in Europe and Russia to Cheplapharm Arzneimittel GmbH for up to $239 million.
The company said Cheplapharm will make an initial payment of $178 million and might make a further payment of up to $61 million subject to future sales, the U.K. pharmaceutical company said.
AstraZeneca said the deal will allow it to focus on its main therapy areas. The company had previously sold rights to the drugs in the U.K., Japan and other major international markets.
AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR--anti-psychotic medicines with antidepressant properties--to Cheplapharm during a transition period,
For 2018, pretax profit attributable to the drugs in Europe and Russia was $86 million, AstraZeneca said.
Write to Adria Calatayud at adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 30, 2019 03:32 ET (07:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
